John Renger - 05 Jul 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 05 Jul 2022
Net transactions value: -$694,545
Form type: 4
Filing time: 07 Jul 2022, 16:06:48 UTC
Previous filing: 15 Apr 2022
Next filing: 22 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$87,500	+25,000	+925%	$3.50^*	27,704	05 Jul 2022	Direct	F1, F2
transaction	CERE	Common Stock	Sale	$750,000	-25,000	-90%	$30.00	2,704	05 Jul 2022	Direct	F1
transaction	CERE	Common Stock	Options Exercise	$3,868	+1,105	+41%	$3.50^*	3,809	06 Jul 2022	Direct	F1
transaction	CERE	Common Stock	Sale	$35,912	-1,105	-29%	$32.50	2,704	06 Jul 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-25,000	-13%	$0.000000	165,875	05 Jul 2022	Common Stock	25,000	$3.50	Direct	F1, F3
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-1,105	-0.67%	$0.000000	164,770	06 Jul 2022	Common Stock	1,105	$3.50	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	Includes 724 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2022.
F3	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.